Abstract
Top panel: meta-analysis (random effects model) for occurrence of end-stage kidney disease in four major outcomes trials of SGLT2 inhibitors in heart failure. Bottom panel: depiction of different mechanisms driving the progression of chronic kidney disease in type 2 diabetes, as compared with chronic heart failure. Drugs that lower intraglomerular pressures may be beneficial in type 2 diabetes (characterized by glomerular hyperfiltration), but detrimental in chronic heart failure (characterized by glomerular hypofiltration).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
